DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin ... - GlobeNewswire (press release)

DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin ...GlobeNewswire (press release)... from the VIPES Phase IIb trial and the OLFUS-VIPES extension study of Viaskin Peanut in peanut-allergic patients were published in the Journal of the American Medical Association (JAMA). After 12 months, treatment with Viaskin Peanut 250 µg ...DBV Technologies (DBVT) Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of ...StreetInsider.comall 2 news articles »